PD-1 Antibodies, Nanjing Legend Biotech, 8th Apr
EPO Patent Bulletin - Pharma (A61K)
Summary
PD-1 Antibodies, Nanjing Legend Biotech, 8th Apr
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
Publication EP3740507A1 Kind: A1 Apr 08, 2026
Applicants
Nanjing Legend Biotech Co., Ltd.
Inventors
ZHANG, Yafeng, WU, Shu, YANG, Shuai, CHOU, Chuan-Chu
IPC Classifications
C07K 16/28 20060101AFI20220718BHEP C12N 5/10 20060101ALI20220718BHEP A61K 39/395 20060101ALI20220718BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.